NASDAQ$CELC
Celcuity Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Celcuity reported a larger net loss in Q1 2025 due to increased R&D and administrative expenses as it advanced multiple clinical trials.
Celcuity posted a net loss of $37.0 million for Q1 2025, primarily driven by a significant increase in research and development expenses related to its Phase 3 trials. Despite no reported revenue, the company maintained a strong cash position of over $205 million, sufficient to fund clinical programs through 2026. The company expects multiple data readouts from its ongoing studies later this year.
- Net loss increased to $37.0 million compared to $21.6 million in Q1 2024.
- Research and development expenses rose to $32.2 million, up from $20.6 million.
- Cash, cash equivalents, and investments totaled $205.7 million at quarter-end.
- Non-GAAP net loss was $34.7 million, excluding stock-based compensation and other non-cash items.
Headline financials
Revenue & EPS history
Celcuity · Revenue · Quarterly
$0
Forward guidance
Celcuity anticipates key clinical milestones in 2025 and is adequately funded to support its development programs through 2026.
Tailwinds
- Topline data from VIKTORIA-1 WT cohort expected in Q3 2025.
- PIK3CA mutant cohort data expected in Q4 2025.
- VIKTORIA-2 trial set to begin dosing in Q2 2025.
- Strong cash position of $205.7 million.
- Collaboration with Dana Farber and MGH initiated for endometrial cancer study.
Headwinds
- Significantly increased operating expenses.
- Lack of revenue generation in the quarter.
- Net loss widened compared to prior year.
- High dependency on trial outcomes for future progress.
- Ongoing need for capital to sustain long-term pipeline.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
-0.9%
Avg return
Earnings day
+0.5%
Avg return
5 days after
+1.8%
Avg return
30 days after
38%
13 / 34 earnings
Positive
+23.3%
Q4 2023
Best reaction
-13.5%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.5% | -4.7% | -32.5% | |
| Q3 2025 | +1.1% | +7.6% | +23.6% | |
| Q2 2025 | +0.1% | -6.0% | +5.8% | |
| Q1 2025 | -2.6% | -1.9% | +11.5% | |
| Q4 2024 | -8.1% | -14.4% | +6.8% | |
| Q3 2024 | -13.5% | -14.8% | -14.5% | |
| Q2 2024 | -6.2% | +3.0% | -10.9% | |
| Q1 2024 | +4.6% | -0.5% | -11.0% | |
| Q4 2023 | +23.3% | +18.6% | -9.1% | |
| Q3 2023 | +11.3% | +18.7% | +37.4% | |
| Q2 2023 | -1.0% | -1.2% | -8.7% | |
| Q1 2023 | +2.2% | +4.7% | +9.5% | |
| Q4 2022 | -5.0% | +3.7% | -3.2% | |
| Q3 2022 | +3.0% | -0.5% | -6.7% | |
| Q2 2022 | -1.0% | -4.3% | -14.2% | |
| Q1 2022 | +2.8% | +6.5% | +57.6% | |
| Q4 2021 | -2.8% | +0.0% | -16.8% | |
| Q3 2021 | -5.9% | -7.7% | -26.6% | |
| Q2 2021 | -1.3% | +2.3% | +5.1% | |
| Q1 2021 | -4.5% | -0.8% | -0.8% | |
| Q4 2020 | +1.1% | +7.4% | -3.9% | |
| Q3 2020 | +0.5% | +64.0% | +93.3% | |
| Q2 2020 | -0.2% | -6.9% | -11.3% | |
| Q1 2020 | -2.4% | -13.8% | +90.3% | |
| Q4 2019 | -4.8% | -3.7% | -23.5% | |
| Q3 2019 | +1.4% | +1.0% | -23.1% | |
| Q2 2019 | +0.7% | -0.4% | -14.9% | |
| Q1 2019 | -2.5% | +0.2% | -6.8% | |
| Q4 2018 | -4.7% | -8.5% | -12.8% | |
| Q3 2018 | -7.2% | -6.2% | -17.8% | |
| Q2 2018 | -1.1% | +2.8% | -15.0% | |
| Q1 2018 | -4.0% | -2.4% | -2.2% | |
| Q4 2017 | -2.4% | -9.9% | +18.6% | |
| Q3 2017 | -5.6% | -15.7% | -13.2% | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q4 2016 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro